FDA.reportPublic FDA data

1 ML tildrakizumab-asmn 100 MG/ML Prefilled Syringe [Ilumya]

RxCUI
2053458
RxNorm name
1 ML tildrakizumab-asmn 100 MG/ML Prefilled Syringe [Ilumya]
Display name
1 ML tildrakizumab-asmn 100 MG/ML Prefilled Syringe [Ilumya]
Full name
1 ML tildrakizumab-asmn 100 MG/ML Prefilled Syringe [Ilumya]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:20

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761067Ilumyatildrakizumab-asmn351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
c6a322bb-51b9-4f0e-8642-62a9682ffcde1 ML tildrakizumab-asmn 100 MG/ML Prefilled Syringe [Ilumya]SBD18These highlights do not include all the information needed to use ILUMYA safely and effectively. See full prescribing information for ILUMYA. ILUMYA ® (tildrakizumab-asmn) injection, for subcutaneous use Initial U.S. Approval: 201820251225
c6a322bb-51b9-4f0e-8642-62a9682ffcdeIlumya 100 MG per 1 ML Prefilled SyringeSY18These highlights do not include all the information needed to use ILUMYA safely and effectively. See full prescribing information for ILUMYA. ILUMYA ® (tildrakizumab-asmn) injection, for subcutaneous use Initial U.S. Approval: 201820251225
c6a322bb-51b9-4f0e-8642-62a9682ffcdeILUMYA 100 MG in 1 ML Prefilled SyringePSN18These highlights do not include all the information needed to use ILUMYA safely and effectively. See full prescribing information for ILUMYA. ILUMYA ® (tildrakizumab-asmn) injection, for subcutaneous use Initial U.S. Approval: 201820251225
c6a322bb-51b9-4f0e-8642-62a9682ffcde1 ML Ilumya 100 MG/ML Prefilled SyringeSY18These highlights do not include all the information needed to use ILUMYA safely and effectively. See full prescribing information for ILUMYA. ILUMYA ® (tildrakizumab-asmn) injection, for subcutaneous use Initial U.S. Approval: 201820251225